Table 1 Summary of NS1 subunit vaccine applications in mouse models

Monoclonal anti-NS1 Abs

DENV2 (NGC) 100 IC₅₀ i.c.

BALB/c

50-93% Survival

[135]

DNA vaccine:

DENV2 (PL046)

C3H/HeN

pD2NS1: 50% Survival

[136]

pD2NS1

10⁷ PFU i. p.

50% Morbidity

pD2NS1 + pIL12

pD2NS1 + pIL12: 80% Survival

20% Morbidity

DNA vaccine: pcTPANS1

DENV2 (NGC)

BALB/c

50% Survival

[137]

4,32 log₁₀PFU i.c.

DNA vaccine: pcTPANS1*

DENV2 (NGC)

BALB/c

pcTPANS1: 96.7% Survival

[138]

pcENS1**

4,32 log₁₀PFU i.c.

10%Morbidity

pcEN1: 86.7% Survival

27% Morbidity

Vaccinia Virus:

DENV4 (H241)

BALB/c

67% Survival

[139]

vNS1-15% NS2a

100IC₅₀ i.c.

rNS1 + CFA (adjuvant)

DENV2 (NGC)

BALB/c

88% Survival

[77]

Lethal dose i.c.

18% morbidity

rNS1 + LT_G33D (adjuvant)

DENV2 (NGC)

BALB/c

50% Survival

[140]

4,32 log₁₀PFU i.c.

80% Morbidity